Anchor Capital Advisors LLC lowered its holdings in NuVasive, Inc. (NASDAQ:NUVA – Get Rating) by 8.9% in the 4th quarter, HoldingsChannel.com reports. The firm owned 20,931 shares of the medical device company’s stock after selling 2,057 shares during the quarter. Anchor Capital Advisors LLC’s holdings in NuVasive were worth $863,000 as of its most recent SEC filing.
Other hedge funds have also bought and sold shares of the company. Asset Dedication LLC acquired a new stake in NuVasive in the 4th quarter valued at $30,000. Point72 Hong Kong Ltd boosted its holdings in NuVasive by 28.3% during the 1st quarter. Point72 Hong Kong Ltd now owns 1,347 shares of the medical device company’s stock worth $76,000 after acquiring an additional 297 shares during the last quarter. Captrust Financial Advisors boosted its holdings in NuVasive by 85.7% during the 1st quarter. Captrust Financial Advisors now owns 2,108 shares of the medical device company’s stock worth $120,000 after acquiring an additional 973 shares during the last quarter. PNC Financial Services Group Inc. boosted its holdings in NuVasive by 76.4% during the 1st quarter. PNC Financial Services Group Inc. now owns 2,175 shares of the medical device company’s stock worth $123,000 after acquiring an additional 942 shares during the last quarter. Finally, Harbor Investment Advisory LLC boosted its holdings in NuVasive by 147.6% during the 4th quarter. Harbor Investment Advisory LLC now owns 2,516 shares of the medical device company’s stock worth $104,000 after acquiring an additional 1,500 shares during the last quarter.
Analyst Upgrades and Downgrades
A number of equities analysts have issued reports on the stock. Wells Fargo & Company downgraded shares of NuVasive from an “overweight” rating to an “equal weight” rating and lifted their price objective for the stock from $47.00 to $57.72 in a report on Friday, February 10th. Piper Sandler downgraded shares of NuVasive from an “overweight” rating to a “neutral” rating in a report on Thursday, February 9th. They noted that the move was a valuation call. Citigroup downgraded shares of NuVasive from a “buy” rating to a “neutral” rating and cut their price objective for the stock from $63.00 to $52.00 in a report on Friday, February 10th. Morgan Stanley lifted their price objective on shares of NuVasive from $44.00 to $44.50 and gave the stock an “equal weight” rating in a report on Thursday, February 23rd. Finally, Truist Financial cut NuVasive from a “buy” rating to a “hold” rating and lifted their target price for the stock from $51.00 to $52.50 in a research note on Friday, February 10th. Ten research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $50.98.
NuVasive Trading Down 0.6 %
NuVasive (NASDAQ:NUVA – Get Rating) last announced its quarterly earnings data on Wednesday, May 10th. The medical device company reported $0.47 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.41 by $0.06. NuVasive had a return on equity of 11.82% and a net margin of 1.66%. The business had revenue of $307.71 million for the quarter, compared to analysts’ expectations of $298.43 million. During the same period in the previous year, the business posted $0.54 EPS. As a group, research analysts anticipate that NuVasive, Inc. will post 2.19 EPS for the current year.
NuVasive Company Profile
NuVasive, Inc engages in the development, manufacture, sale, and provision of procedural solutions for spine surgery. It offers a comprehensive portfolio of procedurally integrated spine surgery solutions, including surgical access instruments, spinal implants, fixation systems, biologics, and enabling technologies, as well as systems and services for intraoperative neuromonitoring.
- Get a free copy of the StockNews.com research report on NuVasive (NUVA)
- 3 Electrical Gear Makers: Hidden Gems Amid Growing Digitization
- Can ULTA’s Defensive Product Line Stand Against This Down Cycle
- A Reversal Is Brewing For Medtronic: Buying The Dip
- Ralph Lauren’s Styled Dividend Is Still In Season
- Dollar Tree Falls As Theft Cuts Into Bottom Line
Want to see what other hedge funds are holding NUVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for NuVasive, Inc. (NASDAQ:NUVA – Get Rating).
Receive News & Ratings for NuVasive Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NuVasive and related companies with MarketBeat.com's FREE daily email newsletter.